XERIS BIOPHARMA HOLDINGS, INC. (XERS) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 335.41M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $335.41M | (m) | (m) |
| 2026-03-31 | (m) | $314.85M | (m) | (m) |
| 2025-12-31 | (m) | $291.85M | (m) | (m) |
| 2025-09-30 | (m) | $266.14M | (m) | (m) |
| 2025-06-30 | (m) | $246.03M | (m) | (m) |
| 2025-03-31 | (m) | $222.55M | (m) | (m) |
| 2024-12-31 | (m) | $203.07M | (m) | (m) |
| 2024-09-30 | (m) | $187.36M | (m) | (m) |
| 2024-06-30 | (m) | $181.41M | (m) | (m) |
| 2024-03-31 | (m) | $171.36M | (m) | (m) |
| 2023-12-31 | (m) | $163.91M | (m) | (m) |
| 2023-09-30 | (m) | $152.67M | (m) | (m) |
| 2023-06-30 | (m) | $134.07M | (m) | (m) |
| 2023-03-31 | (m) | $121.37M | (m) | (m) |
| 2022-12-31 | (m) | $110.25M | (m) | (m) |
| 2022-09-30 | (m) | $98.22M | (m) | (m) |
| 2022-06-30 | (m) | $79.56M | (m) | (m) |
| 2022-03-31 | (m) | $63.14M | (m) | (m) |
| 2021-12-31 | (m) | $49.28M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $20.16M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |